RxDoctor Payments Data

Amber Wolfe, APRN

Family · Ft Cobb, OKNPI 1760757140

Payments from drug & device makers

$599in general payments, 2019–2025

Across 32 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$315
  • GSK$125
  • Myriad Women's Health, Inc.$49
  • Abbott$42
  • Lilly USA, LLC$23
  • Exact Sciences$15
  • plus $30 from 2 others

What the payments were for

  • Speaking & faculty fees$153%
  • Food & beverage$58497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie24$315
GSK1$125
Myriad Women's Health, Inc.1$49
Abbott1$42
Lilly USA, LLC1$23
Exact Sciences1$15
Mckesson Medical-surgical, Inc.1$15
Genentech USA, Inc.2$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$599 in reported general payments places this provider in the 60th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$27,876
Medicare patients
268
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$96,697
OzempicSemaglutide49$60,341
Nurtec OdtRimegepant Sulfate26$55,615
TrulicityDulaglutide23$26,032
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,936
UbrelvyUbrogepant21$20,840
LinzessLinaclotide20$16,624
EliquisApixaban11$15,207
JanumetSitagliptin Phos/Metformin Hcl14$10,894
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,418
Praluent PenAlirocumab12$7,739
Tresiba Flextouch U-200Insulin Degludec12$6,784
BrilintaTicagrelor15$6,458
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,424
TradjentaLinagliptin11$5,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$23$122,72994 claims
AbbVieUbrelvy, Linzess$315$37,46441 claims
GSKTrelegy Ellipta, Arnuity Ellipta$125$26,70944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,026 family providers in Oklahoma.

Other family in Ft Cobb

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →